Introduction
Patients with DLB have cytoplasmic neuronal accumulation of alpha-synuclein, a feature that it shares with other synucleinopathies such as Parkinson's disease (PD). PD dementia (PDD) is primarily distinguished from DLB by the presence of motor symptoms for more than a year prior to cognitive decline [1] . DLB accounts for 5-25 % of dementia [2] [3] [4] [5] [6] . A meta-analysis of epidemiological studies suggests a lower prevalence (3.8-4.5 % of diagnoses), and an incidence of 0.57-1. 4 cases/1,000 person-years [7•]. These are underestimates: the diagnostic criteria have low sensitivity (12-32 %) but high specificity (995 %) [8•] , suggesting that many DLB diagnoses are "missed" [9] .
Establish the diagnosis
The diagnostic symptoms and signs for DLB (Table 1) [1] are of value only when present early in the disease. This is because the same features arise late in other dementia syndromes [8•] . Despite the poor sensitivity in I-Ioflupane (also known as FP-CIT) single-photon emission computed tomography (SPECT), fluorodopa positron emission tomography (PET) and 11 C-dihydrotetrabenazine (DTBZ) positron emission tomography accurately identify the nigral degeneration seen in the synucleinopathies. It is particularly helpful in differentiating the synucleinopathies from other degenerative diseases (and especially Alzheimer's disease) [1, 14, 15] . 123 Iodine-metaiodobenzylguanidine (MIBG) scintigraphy has the same role [16, 17] . Given the frequency of DLB and Alzheimer's disease co-pathology [18] [19] [20] [21] , amyloid PET is not useful in differential diagnosis. The same issue complicates spinal fluid amyloid-beta and tau analysis [18] [19] [20] [21] .
Multifaceted treatment is needed in this complex disease DLB is a complex disease with a wide variety of sequelae that each need consideration for treatment [22, 23] . Many symptoms go unreported because they are nonspecific, and patients incorrectly assume that "physical" and "psychological" symptoms are unrelated to DLB. Treating symptoms with the assumption that they are caused by synucleinopathy is often effective and efficient. For example, a trial of levodopa at bedtime may resolve nocturnal cramps without the discomfort and expense of spinal MRI and electromyography. Given the limitations of current practice models, it is helpful to schedule frequent follow-up visits in the first 3-6 months, with each visit addressing a specific component of the multisystem involvement. iodine-metaiodobenzylguanidine, PET positron emission tomography, SPECT single-photon emission tomography
Cease and avoid treatments likely to exacerbate symptoms Many commonly used medications can produce severe side effects in patients with DLB, notably m e d i c a t i o n s w i t h a n t i c h o l i n e r g i c o r a n t idopaminergic actions. Substantial improvement in quality of life can be achieved by ceasing these treatments.
There are no studies to guide decisions to withdraw therapy in end-stage DLB, and very few treatment trials are specific to DLB, therefore the following draws heavily from the non-DLB evidence base.
Treatment Treatment of cognitive features

Memory and attention
Cholinesterase inhibitors
& The cholinesterase inhibiters (ChEi) rivastigmine and donepezil have class I evidence for efficacy in DLB [24-26, 27•, 28] . Patients with DLB often have a greater treatment response to these medications compared to Alzheimer's disease patients [26, 29] , reflecting the profound reduction in cholinergic function with relative neuronal preservation seen in DLB [30] . & A Cochrane review [28] & Theoretically, ChEi's can exacerbate parkinsonism, however this is rare in practice. They do increase tremor (OR 2.71, p=0.002) [24] , but this is rarely bothersome enough to warrant discontinuation, and global PD severity scores are unaffected (p=0.71) [24] . & Nausea and vomiting are common side effects during initiation of ChEi treatment; they frequently abate with time. The 5HT-3 receptor antagonists (e.g., ondansetron, granisetron) are appropriate short-term remedies, but antiemetics that block dopamine (e.g., prochlorperazine and metaclopramide), and anticholinergic and antihistamine nausea treatments are best avoided in DLB. & Forewarn patients that ChEi treatment may induce vivid dreaming. This can be minimized by avoiding nocte dosing; for the twice daily prepa-rations, morning and early afternoon doses are preferable. & Fluctuations are difficult to manage because they have multiple contributing causes [12] .
Class effects
Contraindications Use with caution in patients with cardiac conduction disorders, severe asthma or obstructive pulmonary disease, peptic ulcer disease, or bladder outflow obstruction.
Main drug interactions Antipsychotics, increased extrapyramidal side effects; beta-blockers, increased bradycardia.
Main side effects Gastrointestinal (GI) distress (10 % of patients: nausea, vomiting, anorexia, weight loss, diarrhea), dizziness, insomnia, vivid dreams, muscle cramps, tremor, weakness, diaphoresis, bradycardia, syncope, falls. & Side effects frequently abate after several weeks.
Rivastigmine
Standard dosage Oral 1.5 mg twice daily to 6 mg twice daily, transdermal 4.6-13.3 mg/24 h.
Contraindications See class effects.
Main side effects Tolerated by 75 % of DLB subjects; see class effects.
Special points Start at 1.5 mg twice daily, increase by 1.5 mg for both doses every 2 to 4 weeks; maximum dose 6 mg twice daily. 
Donepezil
Standard dosage Oral 10 mg once daily.
Main side effects See class effects.
Special points Start at 5 mg daily, increase to 10 mg daily at 4 weeks; may increase further in increments of 5 mg.
& Some patients may respond to higher doses given in twice daily dosing (10 mg in AM and 5 mg in PM). We use multiples of the generic tablets, rather than the expensive 23 mg tablets, although insurers will often refuse to cover more than 10 mg daily dosing. & Patients with vivid dreams may benefit from AM dosing, whereas patients with GI sensitivity may benefit from PM dosing.
Cost 5 mg, 10 mg (30 tablets): $260.
Galantamine
Standard dosage Oral 4 mg twice daily to 12 mg twice daily; extended-release 8 mg daily to 24 mg daily.
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Main drug interactions See class effects.
Main side effects See class effects.
Special points Start at 4 mg twice daily, increase in 4 mg increments for both doses over 2 to 4 weeks; maximum dose 12 mg twice daily or 24 mg daily for extended-release formulation.
Cost N-methyl-D-aspartic acid receptor antagonists & Memantine produced small and significant improvements in global clinical impression scores in DLB/PDD cohorts [35•, 36] . However, these findings were not consistent over the duration of the study in one trial [35•] , and sub-group analysis of the other suggested that the overall results were due to improvements in the PDD patients only [36] .
Memantine
Standard dosage Oral 5 mg daily to 10 mg twice daily; extended-release 7 mg daily to 28 mg daily.
Contraindications Use with caution in patients with severe hepatic impairment or renal impairment.
Main drug interactions Memantine may increase serum concentrations of buproprion and trihexyphenidyl. Trimethoprim and memantine mutually increase serum drug levels, possibly increasing risk of confusion and myoclonus due to the latter. Sodium bicarbonate and carbonic anhydrase inhibitors decrease the excretion of memantine.
Main side effects GI side effects (constipation, nausea, vomiting), dizziness, confusion, headache, hallucinations, aggression, pain, hypertension, and heart failure. Antidepressant medications: SSRIs, SNRIs, bupropion
Special points
Selected SSRIs, SNRIs and bupropion are prescribed frequently for depression and/or anxiety in DLB. General principles of starting at a low dose, increasing the dose gradually, and monitoring closely for side effects should be followed.
Class effects SSRIs
Contraindications Concomitant use with a MAOi, pimozide. 
Main drug interactions
Citalopram
Standard dosage Oral 10-20 mg daily.
Main drug interactions See class effects; primarily metabolized by CYP2C19, 2D6 and 3A4.
Special points Start at 10 mg daily, may increase to 20mg after 1 month if necessary. Doses greater than 20 mg are not recommended since they increase the risk of QTc prolongation without improving outcomes.
& Relatively selective for serotonin reuptake inhibition
Cost 10 mg, 20 mg, 40 mg (100 tablets): $255.
Escitalopram
Standard dosage Oral 5 mg daily to 20 mg daily.
Main drug interactions See class effects; primarily metabolized by CYP2C19 and 3A4.
Main side effects See class effects.
Special points Start at 5 or 10 mg daily; may increase in increments of 5 or 10 mg over intervals of at least 1 week; maximum dose 20 mg daily.
& Relatively selective for serotonin reuptake inhibition & Fewer drug interactions than other SSRIs
Cost 5 mg, 10 mg, 20 mg (100 tablets): $450.
Venlafaxine (SNRI)
Standard dosage Oral 37.5-225 mg/day in two to three divided doses or with single extendedrelease preparation.
Contraindications Concomitant use with a MAOi.
Main drug interactions CYP2D6 or 3A4 inhibitors; other serotonergic drugs (see SSRI class effects above), a MAOi.
Main side effects GI side effects (anorexia, nausea, constipation), sleep side effects (somnolence, insomnia, RBD), dry mouth, increased sweating, dizziness, fatigue, headache, nervousness.
Special points Start at 37.5 or 75 mg daily; may increase in increments of 37.5 mg over intervals of at least 1 week. 
Bupropion (dopamine-norepinephrine reuptake inhibitor)
Standard dosage Oral 100 mg daily to 450 mg daily in three to four divided doses (immediaterelease), two divided doses (sustained-release), or single dose (extended-release).
Contraindications Concomitant use with a MAOi; seizure disorder.
Main drug interactions CYP2B6 inducers (some anticonvulsants, rifamycin antibiotics) or inhibitors, cyclosporine, MAOis.
Main side effects GI side effects (nausea), sleep side effects (insomnia), dry mouth, headache, anxiety, agitation, tremor, seizure. 
Special points
Hallucinations and delusions
& Sixty to seventy percent of patients experience hallucinations [22, 49] . They distinguish DLB from Alzheimer's only if present in the first years of illness [50] . They are often not bothersome to patients, who frequently retain insight into their non-veridicality, but patients and caregivers often argue over their veridicality if insight is lost. Education of caregivers in the use of distraction techniques to "change the subject" is anodyne in these situations. & Regular vision correction and the use of bright lights in the evening and no lights at night may decrease their frequency. & The first step in medication adjustment should be the stepwise, gradual reduction of medications that have the potential to exacerbate neuropsychiatric symptoms, in the following order: anticholinergic medications, amantadine, dopamine agonists, MAOis, COMT inhibitors, and levodopa/carbidopa. They should be decreased slowly to avoid the possibility of neuroleptic malignant syndrome [51] . & The second step is the introduction of or increase in ChEi therapy. This reduces hallucinations in 990 % of PDD patients [25] .
Electing not to use neuroleptics is often the best course of action & They rarely treat the hallucinations effectively [52] [53] [54] . & They increase risk of stroke, sudden cardiac death and overall mortality in dementia populations [55] [56] [57] . In a meta-analysis of 10-12 week trials of all-cause dementia (combined subject N=5,110), death occurred in 3.5 % of treated dementia subjects, and 2.3 % of controls, resulting in a number needed to harm of 100 (range 53-1,000) and a number needed to treat of 4-12 [58] . Weighing against this, a recent observational study found that after controlling for important risk factors such as cardiovascular risk and severity of psychosis, antipsychotic use was not associated with premature death [59] . & The outcomes for antipsychotic treatment are sometimes worse in DLB: 30-50 % of patients experience sensitivity reactions, including increased parkinsonism and severe rigidity, dysautonomia, confusion and prolonged periods of decreased responsiveness [1, [60] [61] [62] . These may be fatal [60, 62] , may occur after a single dose, and after most antipsychotics (e.g., adverse reaction frequencies: olanzapine 58%, clozapine 11 %, thioridazine 6 %) [60, 63, 64] . & Despite these concerns, antipsychotic medications are used more frequently in DLB than in Alzheimer's [65] , presumably when quality of life is so severely affected that safety concerns are considered of less significance.
A programmed trial of cessation should accompany all prescriptions 
Choice of antipsychotic
& Limited data exist for DLB. Meta-analyses of all-cause dementia patients (N95,000) mostly aged in their 80s and in nursing facilities suggest that aripiprazole and risperidone are effective, olanzapine ineffective, and the evidence for quetiapine is mixed [53] . Differences in treatment versus placebo were only marginal in their clinical significance, but 25-30 % improvements were also seen in the placebo groups (hence the value of programmed treatment cessation 
Carbamazepine
Standard dosage 200-800 mg twice daily.
Contraindications Bone marrow suppression; concomitant use of a MAOi; concomitant use of nonnucleoside reverse transcriptase inhibitors; hypersensitivity to tricyclic compounds.
Main drug interactions
Medications associated with CYP1A2, 2B6, 2C, 3A4 pathways, of which carbamazepine is an inducer.
Main side effects Dizziness, drowsiness, tremor, nausea, hyponatremia, rash, diplopia, blurred vision, confusion, change in blood pressure, myelosuppression, hepatitis. 
Special points
Divalproex sodium
Standard dosage 250-1,000 mg daily, administered once daily (extended-release) or twice daily (delayed-release).
Contraindications Liver disease, urea cycle disorders.
Main drug interactions Medications associated with CYP2C9/10, 2C19 pathways (includes lacosamide); lamotrigine, serotonergic agents.
Main side effects Somnolence, dizziness, alopecia, changes in weight, abdominal pain, GI side effects (diarrhea, loss of appetite, nausea, vomiting), fatigue, ataxia, headache, tremor, diplopia, confusion. 
Special points
Treatment of motor dysfunction
& Minimize parkinsonism due to antipsychotic medications, nausea treatments (e.g., prochlorperazine, metoclopramide), and anticholinergic tremor medications (e.g., trihexyphenidyl, benztropine) [83] . & Nocturnal parkinsonism with inadequate nocturnal levodopa may disrupt sleep, alter sleep architecture, allow painful muscular cramps, and place subjects at risk of falls upon waking. & L-dopa replacement is less effective in DLB than for PD [84, 85] . It is more likely to induce psychosis in DLB patients [84, 85] , though this tends to occur only with high doses. In cases where neuropsychiatric features predominate, it is wise to accept minor parkinsonism rather than risk treatments that worsen these symptoms. & Late in the disease, when maximal treatment of neuropsychiatric symptoms with ChEis +/− antipsychotic medication fails to control the side effects of dopaminergic therapy, a choice is forced between directing therapy toward the motor or neuropsychiatric features. Patients and caregivers find it easier to accept this dilemma if they are educated about it early in the treatment process. Neuropsychiatric features usually limit treatment well before dopa-induced dyskinesias arise, but we educate patients about these nevertheless. & Oral dopamine agonists frequently cause hallucinations, impulse dyscontrol and abnormal repetitive behaviors [64] ; they should be avoided in this population. There is insufficient evidence to determine if transdermal formulations (e.g., rotigotine transdermal patch) are effective and/or well-tolerated. Levodopa is significantly less likely to induce hallucination and behavioral problems, but can do so at high doses. Mixed evidence suggests that amantadine may reduce their severity, but may also induce postural hypotension, confusion, insomnia and hallucinations [44••] .
Carbidopa/levodopa
Standard dosage 25/100 mg, 1-3 tablets three times daily.
Contraindications Concomitant use with a MAOi; narrow-angle glaucoma; current diagnosis of melanoma.
Main drug interactions Antipsychotics, iron supplements.
Main side effects Nausea, vomiting, anorexia, lightheadedness, hypotension, confusion, hallucinations, dyskinesia, axonal polyneuropathy.
Special points Start with a half-tablet three times daily, increase in half-tablet increments for all doses weekly, maximum dose 3 tablets every 6 h.
• Use the minimal dose required, review regularly and slowly increase as necessary.
• Carbidopa/levodopa competes with protein for absorption: take 1 h before, or 2 h after a meal; if nausea develops, take with protein-poor snacks (e.g., soda crackers).
• Carbidopa/levodopa interferes with vitamin metabolism, supplement with: -Folic acid, 2.5 mg -Vitamin B12, 2 mg -Vitamin B6, 25 mg (warn patients that 9100 mg is neurotoxic).
• To prevent osteoporosis, if patient has no history of calcium-containing renal stones: -Vitamin D: 1,000 U daily -Calcium: 1,200 mg (1,500 mg for postmenopausal women or men with osteoporosis)
Cost 25/100 mg (100 tablets): $80.
Treatment of autonomic dysfunction
Constipation & This is an uncomfortable, under-recognized and poorly treated feature of synucleinopathy: 80-89 % of PD patients report constipation and/or diarrhea, and 16 % have been hospitalized for bowel obstruction [86, 87] . Although most cases of constipation are secondary to decreased colonic transit and gastrointestinal dysmotility, anorectal dysfunction (dyssenergy) may contribute significantly in a small set of subjects. [89] . & Alternatives include methylcellulose, docusate, magnesium hydroxide, and misoprostol [51] . & A recent double-blind, 4-week study found significant improvement with the use of the chloride channel activating agent lubiprostone [90] .
Psyllium
Standard dosage 5.1 g twice daily (mixed with 8 oz of water).
Contraindications Bowel obstruction.
Main drug interactions TCAs.
Main side effects Gastrointestinal obstruction, nausea, bloating, and diarrhea. 
Polyethylene glycol (Macrogol)
Standard dosage 17 g (powder dissolved in 4-8 oz of water, juice, coffee or tea) daily.
Contraindications Bowel obstruction.
Main drug interactions None.
Main side effects Bloating, cramping, diarrhea, and nausea. 
Lubiprostone
Standard dosage 24 mcg twice daily.
Contraindications Bowel obstruction.
Main side effects Nausea, diarrhea, flatulence; headache, and edema. ; perform 24-h blood pressure monitoring intermittently to detect malignant supine hypertension. A simple remedy for this is to raise the head of the bed, either by purchasing an expensive motordriven bed, or by placing bricks under the head of the existing one (a cheaper option). & Midodrine may be added second-line, however there are no data to suggest one treatment over another [51] .
Fludrocortisone
Standard dosage Oral 0.1 mg every other day to 1 mg daily.
Contraindications Supine systolic hypertension 9180 mmHg; hypersensitivity to corticosteroids; congestive heart failure, systemic fungal infections.
Main drug interactions Bupropion (may lower seizure threshold).
Main side effects Peripheral edema, hypertension, depression, delirium, psychosis, anxiety, bruising, rash, hyperpigmentation, hyperglycemia, hypokalemia, hypokalemic alkalosis, and osteoporosis. 
Midodrine
Standard dosage 10 mg three times daily.
Contraindications Significant heart disease; severe urinary retention.
Main drug interactions TCAs, MAOis, ergot derivative medications; sympathomimetic agents.
Main side effects Supine hypertension, piloerection, pruritus, dysuria or urinary retention, paresthesias.
Special points Start at 2.5 mg or 5 mg twice daily or three times daily, increase in increments of 2.5 mg over intervals of at least 5 days; maximum dose 10 mg three times daily. 
Indomethacin
Standard dosage 25-200 mg daily in two to four divided doses.
Contraindications Bleeding disorder; anticoagulants.
Main drug interactions NSAIDS, ACE inhibitors, lithium, SSRIs, methotrexate, loop diuretics, cyclosporine.
Main side effects Dizziness, headache, fatigue, and dyspepsia.
Special points & Begin at low dose and titrate to achieve desired effect. & Increases risk of cardiac events and gastrointestinal bleeding.
Cost 25 mg (100 tablets): $38.
Genito-urinary symptoms
& Urinary frequency, urgency and incontinence are common problems in DLB. There is scant data in DLB patients [1, 94] , but they occur in 57-83 % of PD patients, and hesitancy or reduced urinary stream occurs in 17-27 % [95] . & Oral trospium or transdermal oxybutynin are effective treatments of detrusor instability. Trospium is less likely than oxybutynin to cross the blood-brain barrier based on its polarity. Alternatives include tolterodine, flavoxate, propiverine, prazosin and desmopressin [44••] . & Avoid the anticholinergic treatments such as trihexyphenidyl and oral oxybutynin, which may cause confusion [22, [96] [97] [98] . & Other conditions [51] :
-Prostatism: tamsulosin.
-Urinary retention: bethanechol chloride 25-75 mg/day. -Nocturnal polyuria: intranasal desmopressin 10-40 mcg/night.
Trospium chloride
Standard dosage 20-60 mg daily in two doses or single dose of extended-release.
Contraindications Gastric retention, uncontrolled narrow-angle glaucoma, and urinary retention.
Main drug interactions Oral potassium, metformin, vancomycin, tenofovir, procainamide, pancuronium, morphine, and cisapride.
Main side effects Dizziness, blurred vision, impaired heat regulation, constipation, xerostomia, headache, and angioedema. . & Other physicians may need to be appraised of the reasons for combination of stimulants and sedatives in some patients (e.g., the presence of REM sleep behavior and excessive daytime sleepiness), and optimal management usually requires iterative treatment to arrive at a regime suitable for the individual.
Methylphenidate
Standard dosage Oral 5-60 mg daily in two doses or single dose of extended-release.
Contraindications Glaucoma, concomitant use of a MAOi, marked agitation or anxiety, and Tourette's syndrome.
Main drug interactions MAOis, bupropion, tricyclic antidepressants, SSRIs, carbamazepine, phenytoin, phenobarbital, primidone, tyrosine, dicumarol, warfarin
Main side effects Weight loss, nausea, vomiting, insomnia, blurred vision, dizziness, tics, labile affect, and nasal congestion.
Special points Start at 5 mg daily in the morning, increase to 5 mg twice daily after 1 week with second dose around noon; may increase daily dose in increments of 5-10 mg over intervals of 1 week.
& Perform an electrocardiogram at initiation and dose increases; monitor pulse and blood pressure. 
Modafinil
Standard dosage 100-400 mg daily in single dose or two doses.
Contraindications Hypersensitivity.
Main drug interactions CYP2C19 substrates (modafinil is a strong inhibitor), CYP1A2 substrates, CYP3A4 inducers or inhibitors (modafinil is a substrate).
Main side effects Nausea, xerostomia, anorexia, dizziness, headaches, insomnia, and hypertension.
Special points Patients/caregivers should report chest pain, palpitations, agitation, anxiety, psychosis, mania, and depression.
Cost 100 mg (30 tablets): $662, 200 mg (30 tablets): $1,000.
Armodafinil
Standard dosage 150-250 mg daily.
Main drug interactions CYP2C19 substrates (armodafinil is a moderate inhibitor), CYP3A4 inducers or inhibitors (armodafinil is a substrate).
Main side effects Nausea, diarrhea, xerostomia, dizziness, headaches, and insomnia.
Special points Patients/caregivers should report palpitations, psychosis, mania, depression, and anxiety. 
Melatonin
Standard dosage 3-12 mg nocte.
Contraindications Autoimmune disease, lactose intolerance, hepatic impairment.
Main drug interactions CYP1A1 and CYP 1A2 inhibitors or inducers, decreased metabolism of melatonin: fluvoxamine, methoxsalen, cimetidine, estrogen.
Main side effects Morning drowsiness, headache, back pain, arthralgia, nasopharyngitis. Contraindications Hepatic impairment, untreated acute-angle glaucoma.
Special points
Main drug interactions Anti-epileptic medications.
Main side effects Sedation and drowsiness (up to 50 % of patients when starting therapy) [101] , confusion, and paradoxical agitation. Other treatments (centered on behavioral management)
Person-centered care
& An effective care model that strives to remedy unmet needs or invalidated experiences [110] Prescribed social interaction, music, and tape recordings of loved-ones 
